Non-thyroidal Second Primary Malignancy in Papillary Thyroid Cancer Patients

Overview

Journal Eur Thyroid J

Specialties Endocrinology
Oncology

Date 2022 Jul 28

PMID 35900869

Authors

Diana Borges Duarte

Vania Benido Silva

Guilherme Assuncao

Andre Couto Carvalho

Claudia Freitas

Affiliations

Soon will be listed here.

Abstract

Introduction: The occurrence of non-thyroidal second primary malignancy (NTSPM) in patients with papillary thyroid cancer (PTC) is well documented, but epidemiological data are conflicting.

Objective: The aim of this study was to evaluate the incidence of NTSPM in a large series of patients with PTC and to assess its potential risk factors.

Methods: Single-center cohort study with retrospective data collection conducted on consecutive PTC patients diagnosed from 1988 to 2018 with a minimum follow-up time of 2 years. NTSPM was defined as any primary malignancy with histological confirmation occurring in an anatomical site other than the thyroid. According to the timing of occurrence, NTSPM were subdivided into anachronous, synchronous or metachronous (diagnosed >6 months before, within 6 months and >6 months after PTC diagnosis, respectively).

Results: We included 773 individuals (83.3% females), median age at PTC diagnosis was 47.0 (IQR: 37.0-58.0) years and median follow-up time was 9.9 (6.2-16.3) years. Incidence of NTSPM was 15.5% (n = 120) and its standard incidence ratio (SIR) was higher when compared to the general population (SIR: 2.70). Family history of malignancy and younger age at diagnosis were associated respectively with 206 and 4% increased risk of developing metachronous neoplasia (HR: 2.06 (95% CI: 1.10-3.86) and 1.04 (95% CI: 1.02-1.05), respectively).

Conclusion: In our series, the occurrence of NTSPM was not uncommon and its incidence was higher compared to the general population. First-degree family history of malignancy was a strong risk factor for multiple primary malignancies.

Citing Articles

Concurrent identification of follicular lymphoma and papillary thyroid carcinoma.

AlZelfawi L, Alhumaidan N, Alageel A, Yahya B, Alrasheedi S, Alqahtani A Int J Surg Case Rep. 2024; 122:110009.

PMID: 39137643 PMC: 11372620. DOI: 10.1016/j.ijscr.2024.110009.

References

Hirosawa R, Marivo M, Luengo J, Tagliarini J, Castilho E, de Alencar Marques M . Does radioiodine therapy in patients with differentiated thyroid cancer increase the frequency of another malignant neoplasm?. ISRN Oncol. 2011; 2011:708343. PMC: 3200138. DOI: 10.5402/2011/708343. View

Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T . CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004; 75(6):1131-5. PMC: 1182149. DOI: 10.1086/426403. View

Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C . Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer. Thyroid. 2016; 26(8):1110-6. DOI: 10.1089/thy.2016.0037. View

Khang A, Cho S, Choi H, Ahn H, Yoo W, Kim K . The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf). 2014; 83(1):117-23. DOI: 10.1111/cen.12581. View

Ikeda Y, Kiyotani K, Yew P, Kato T, Tamura K, Yap K . Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocr Relat Cancer. 2015; 23(3):171-9. PMC: 5152685. DOI: 10.1530/ERC-15-0359. View

Lang B, Wong I, Wong K, Cowling B, Wan K . Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012; 151(6):844-50. DOI: 10.1016/j.surg.2011.12.019. View

Gandhi S, Abhyankar A, Basu S . Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables. Nucl Med Commun. 2013; 35(2):205-9. DOI: 10.1097/MNM.0000000000000033. View

Bolf E, Sprague B, Carr F . A Linkage Between Thyroid and Breast Cancer: A Common Etiology?. Cancer Epidemiol Biomarkers Prev. 2018; 28(4):643-649. DOI: 10.1158/1055-9965.EPI-18-0877. View

Luo Y, Tsuchiya K, Il Park D, Fausel R, Kanngurn S, Welcsh P . RET is a potential tumor suppressor gene in colorectal cancer. Oncogene. 2012; 32(16):2037-47. PMC: 3465636. DOI: 10.1038/onc.2012.225. View

10.

Ko K, Kao C, Lin C, Huang W, Yen R . (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study. Eur J Nucl Med Mol Imaging. 2015; 42(8):1172-8. DOI: 10.1007/s00259-015-3055-0. View

11.

Endo M, Liu J, Dougan M, Lee J . Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset. J Thyroid Res. 2018; 2018:8765369. PMC: 6038658. DOI: 10.1155/2018/8765369. View

12.

Brown A, Chen J, Hitchcock Y, Szabo A, Shrieve D, Tward J . The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2007; 93(2):504-15. DOI: 10.1210/jc.2007-1154. View

13.

Sandeep T, Strachan M, Reynolds R, Brewster D, Scelo G, Pukkala E . Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006; 91(5):1819-25. DOI: 10.1210/jc.2005-2009. View

14.

Hakala T, Sand J, Jukkola A, Huhtala H, Metso S, Kellokumpu-Lehtinen P . Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int J Clin Oncol. 2015; 21(2):231-239. DOI: 10.1007/s10147-015-0904-6. View

15.

Souza M, Momesso D, Vaisman F, Vieira Neto L, Martins R, Corbo R . Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?. Arch Endocrinol Metab. 2015; 60(1):9-15. PMC: 10118921. DOI: 10.1590/2359-3997000000078. View

16.

Omur O, Ozcan Z, Yazici B, Akgun A, Oral A, Ozkilic H . Multiple primary tumors in differentiated thyroid carcinoma and relationship to thyroid cancer outcome. Endocr J. 2008; 55(2):365-72. DOI: 10.1507/endocrj.k07e-058. View

17.

Teng C, Hu Y, Chen S, Yeh C, Chiang H, Chen T . Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study. J Natl Cancer Inst. 2015; 108(2). DOI: 10.1093/jnci/djv314. View

18.

Berthe E, Henry-Amar M, Michels J, Rame J, Berthet P, Babin E . Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2004; 31(5):685-91. DOI: 10.1007/s00259-003-1448-y. View

19.

Lang B, Wong K . Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma. Ann Surg Oncol. 2011; 18(13):3559-65. PMC: 3222830. DOI: 10.1245/s10434-011-1777-1. View

20.

Rubino C, De Vathaire F, Dottorini M, Hall P, Schvartz C, Couette J . Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89(9):1638-44. PMC: 2394426. DOI: 10.1038/sj.bjc.6601319. View